: iStockAnalyst.com Symbols Feed

How To Spend $95 in Biotech

Wed, 18 Mar 2009 03:19:00 GMT

Sometime during the middle of the year, Genentech (DNA) shareholders are going to get $95 in cash for each share of Genentech stock they own. In total, nearly $47 billion in funds are expected to be returned to biotechnology investors. We've come up with an effective "basket approach" to re-deploy those funds back into the biotech sector -- in search of the next Genentech. Antisense Makes a Lot of Sense For a little over $13, investors can pick up one share of Isis Pharmaceuticals (ISIS). Isis is the market leader in antisense[More...]

Earnings Preview For Mar 16 - 20

Fri, 13 Mar 2009 21:27:00 GMT

Guess, Inc. (GES) could top expectations. FedEx Corporation (FDX) could disappoint. Adobe Systems (ADBE), Nike (NKE) and Oracle (ORCL) will also report. The earnings calendar is limited this week with just 93 companies confirmed to report. First-quarter earnings season will[More...]

Four Healthy Stocks Trading Above Moving Averages

Wed, 31 Dec 2008 15:29:00 GMT

Amgen (AMGN), AspenBio Pharma (APPY), BioDelivery Sciences (BDSI), and Cypress Bioscience (CYPB) are four healthcare stocks that I follow which are poised to close out a rough 2008 for the overall market trading above their 50 and 200-day moving averages, in addition to having significant catalysts in 2009 which may lead to further gains. Below is a summary of the 2009 catalysts for these companies and click on the names or tickers below for a link to all of the articles on my blog for each stock: Amgen filed a BLA for bone drug denosumab in the following two indications: the treatment + prevention of osteoporosis in post-menopausal women and the treatment + prevention of bone loss in patients undergoing hormone ablation for either prostate or breast cancer, with the potential for over $3B in peak sales for the drug based on S&P analyst estimates. AMGN has also posted strong[More...]

Five Healthcare Stocks for a Happy New Year

Tue, 23 Dec 2008 13:27:00 GMT

The accompanying table includes a basket of five small-cap stocks chosen from the ETF Innovators (ETFI) new healthcare indexes. The five companies are trading above their 50-day moving averages with expected upside catalyst(s) in the next six months or less. AMAG Pharma (AMAG) announced last evening that the FDA issued another complete response for its iron deficiency anemia drug ferumoxytol (Feraheme). More details are expected today at 8:30 AM (ET) when AMAG[More...]

UpDown Virtual Investing: Earn Real Money with Zero Risk

Fri, 19 Dec 2008 16:40:00 GMT

Start earning real money with zero risk while improving your trading skills and strategies at the UpDown Virtual Investing website -- just click on the image above or any of the text links to the site in this article to sign up today. My stats and profile are featured in the accompanying table and on my blog site below the last posted entry. I started trading at the UpDown 26 days ago with a gain of about 27% through today -- my profile name on[More...]

A Coiled Spring: Near-Term Catalysts & Oversold Stocks

Wed, 03 Dec 2008 16:54:00 GMT

AMAG Pharma (AMAG) more than doubled on word that the FDA accepted its complete response for a NDA of iron-deficiency anemia drug ferumoxytol in patients with chronic kidney disease and will issue a final ruling before year-end. The news is a major relief for AMAG as no new clinical trials were required and the quick decision deadline before year-end is encouraging for the approval prospects of ferumoxytol. A trio of companies expect FDA decisions for abuse-resistant pain drugs before year-end, including Pain Therapeutics (PTIE) + King Pharma (KG) for Remoxy and Alpharma (ALO) for Embeda. Now that Alpharma has accepted King's buyout bid, the latter reflects a way to trade both decisions in a single stock for twice the chances of approval. Caraco Pharma (CPD) offers U.S. investors a way to play India-based Sun Pharma's growth through their distribution agreement and the Company believes it has addressed the issues raised in the FDA warning[More...]

Stock Opportunities in a 'Roadhouse Blues' Market

Fri, 21 Nov 2008 15:34:00 GMT

The fear and pessimism behind major selling pressure and stock market losses can be summarized by the late Jim Morrison in a song by The Doors called 'Roadhouse Blues' – "The future's uncertain, and the end is always near." Some stocks that I follow which are trading at less than half of the 20% decline for the S&P 500 ETF (SPY) below its 50-day moving average are highlighted below. Earlier this week, AspenBio Pharma (APPY) reported that its key clinical trial was nearly 90% enrolled for AppyScore, which is a blood-based diagnostic screening test for appendicitis. APPY expects to reach the required total of 800 patients within weeks, report topline results 4-6 weeks after enrollment is complete, and file a 510(k) with the FDA in early 2009 – which is a quicker approval process for medical devices and tests compared to the PMA process. APPY is currently trading at its 50-day moving average of around 5 bucks, which is impressive given overall[More...]

A Backlog Of Decisions Is Building At The FDA

Fri, 07 Nov 2008 15:43:00 GMT

The accompanying table presents 70 FDA product approval decision dates along with the market caps and one year stock price change for the underlying companies. A note of caution for investors and traders is that the most common outcome from the FDA in the past year has been a delay in decisions due to understaffed conditions at the agency. However, several companies have pending decisions which are likely to occur either before year-end or early next year and will have a major impact on their stock prices. Discovery Labs (DSCO) submitted its complete response to the FDA in response to a May approvable letter for Surfaxin three weeks ago on 10/17 and had expected the agency to respond last week on the[More...]

Eight White Hot Stocks You Should Know About

Mon, 29 Sep 2008 14:53:00 GMT

This was sent premarket to all TIMalert subscribers:Nothing truly great to start the week off, I’m still in the Florida Keys and I’m gonna go skydiving today…don’t worry, I’ve already been twice, it’s a piece of cake…IDEV got positive drug news and a hunk of money form a major pharmaceutical, I’m not gonna be so quick to short such a power packed deal, of course it could reverse, but I prefer shorting hype and manipulation to real deals like this. That said, if it goes up and squeezes some shorts enough, it’s a potential play.LSCG is a two-day spiker, chart is decent for a reversal but there is a shareholder meeting this Thursday so it’s not ideal (news could be announced).CYPB has the right longterm downtrending chart, spike off the bottom, but a history of taking weeks to reverse after[More...]

Forest, Cypress Revise Timing for Commercial Availability of Savella

Fri, 06 Mar 2009 14:44:26 GMT

US-based pharmaceutical company Forest Laboratories and Cypress Bioscience have said that they expect to ship Savella(TM) (milnacipran HCl), a selective serotonin and norepinephrine reuptake inhibitor for the management of fibromyalgia, to wholesalers and pharmacies by mid 2009.[More...]

Cypress Bioscience Announces Third Quarter 2009 Financial Results

Mon, 09 Nov 2009 10:47:00 GMT

Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced financial results for the third quarter of 2009.
At September 30, 2009, the Company had cash, cash equivalents and investments totaling $144.8 million.
The Company reported revenues of $6.1 million and $19.7 million for the quarter and nine months ended September 30, 2009, respectively, compared to $1.0 million and $16.2 million for the same periods in 2008.

[More...]

Cypress Bioscience Announces Second Quarter 2009 Financial Results

Mon, 10 Aug 2009 10:47:00 GMT

Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced financial results for the second quarter of 2009.
At June 30, 2009, the Company had cash, cash equivalents and investments totaling $151.3 million.
"The launch of Savella in April 2009 represents the culmination of our efforts to bring to market a valuable new treatment for patients suffering from fibromyalgia, which is a chronic and often debilitating condition," said Jay Kranzler, Chairman and CEO of Cypress Bioscience.

[More...]

StockPreacher.com Issues Trading Outlook for Orexigen Therapeutics Inc.

Fri, 24 Jul 2009 10:45:00 GMT

StockPreacher.com announces an investment report featuring biopharmaceutical company Orexigen Therapeutics Inc. . The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.[More...]

Cypress Bioscience, Inc. to Present at Jefferies 3rd Annual Healthcare Conference

Tue, 16 Jun 2009 10:25:00 GMT

SAN DIEGO, CA -- -- 06/16/09 -- Cypress Bioscience, Inc. today announced that Sabrina Martucci Johnson, its Chief Operating Officer and Chief Financial Officer, will present at the Jefferies 3rd Annual Healthcare Conference on June 18, 2009.[More...]

Cypress Bioscience, Inc. Announces First Quarter 2009 Financial Results

Mon, 11 May 2009 10:47:00 GMT

Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced financial results for the first quarter of 2009.
At March 31, 2009, the Company had cash, cash equivalents and investments totaling $160.4 million.
The Company reported revenues of $7.9 million for the quarter ended March 31, 2009 compared to revenues of $14.2 million for the same period in 2008.

[More...]

Cypress Bioscience, Inc. CEO Jay Kranzler Named Ernst & Young Entrepreneur Of The Year(R) Finalist in San Diego

Mon, 11 May 2009 10:25:00 GMT

SAN DIEGO, CA -- -- 05/11/09 -- Cypress Bioscience, Inc. today announced that its Chairman and CEO, Dr. Jay Kranzler, has been named as a finalist for the Ernst & Young Entrepreneur Of The Year® 2009 Award in the San Diego program. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Dr. Jay Kranzler was selected as a finalist from nearly 100 nominations by a panel of independent judges. Award winners will be announced at a special gala event on June 3, 2009 at the Hyatt Regency La Jolla.[More...]

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)

Mon, 20 Apr 2009 11:58:00 GMT

Forest Laboratories, Inc. and Cypress Bioscience, Inc. announced today that Savella , a selective serotonin and norepinephrine dual reuptake inhibitor approved for the management of fibromyalgia, will be shipped to wholesalers on April 24th and will be available at pharmacies beginning on April 28th. After Savella was approved by the U.S. Food and Drug Administration on January 14, 2009, the companies submitted a minor post-approval cosmetic formulation change to the FDA which now has been approved.[More...]

Cypress Bioscience, Inc. to Present at Citi's 4th Annual Biotech Day

Mon, 30 Mar 2009 10:25:00 GMT

SAN DIEGO, CA -- -- 03/30/09 -- Cypress Bioscience, Inc. today announced that Michael R. Hufford, PhD, its Vice President of Corporate Development, will present at Citi's 4th Annual Biotech Day on April 1, 2009.[More...]

Zacks Analyst Blog Highlights: Cypress Biosciences, Forest Labs, ArvinMeritor, Apogee Enterprises and The Macerich Company - Mar 18 2009 7:17AM

Wed, 18 Mar 2009 11:12:00 GMT

Zacks.com announces the list of stocks featured in the Analyst Blog.
Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include: Cypress Biosciences (NASDAQ: CYPB), Forest Labs (NYSE: FRX), ArvinMeritor (NYSE: ARM), Apogee Enterprises (NASDAQ: APOG) and The Macerich Company (NYSE: MAC).

[More...]

Cypress Bioscience, Inc. to Present at Cowen and Company 29th Annual Health Care Conference

Wed, 18 Mar 2009 10:25:00 GMT

SAN DIEGO, CA -- -- 03/18/09 -- Cypress Bioscience, Inc. today announced that Sabrina Martucci Johnson, its Chief Operating Officer and Chief Financial Officer, will present at the Cowen and Company 29th Annual Health Care Conference on March 19, 2009.[More...]